Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$19.6MCash on Hand
9.8mo Cash Runway
Follow CRVO by emailGet an email when CRVO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CRVO, unsubscribe in one click. Privacy
📣 What CRVO Says Is Next
in March 2027 · Neflamapimod: “We expect to report biomarker data from the 80 mg BID dose UK cohort and clinical results at the AD/PD conference in March 2027.” The Phase 2a clinical trial of neflamapimod for the treatment of nfvPPA was designed to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in participants with nfvPPA.”
Company press release, Nov 16, 2026 · SEC filing
by the end of 2026 · Neflamapimod: “RAS: CervoMed expects to obtain topline data from its Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke by the end of 2026. 2 Third Quarter 2026 Financial Results Cash Position: As of September 30, 2026, CervoMed had approximately $19.6 million in cash, cash equivalents, and marketable securities, as compared to $20.9 million as of December 31, 2025.”
Company press release, Nov 9, 2026 · SEC filing
fourth quarter of 2026 · “The Company also expects to initiate the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.”
Company press release, Oct 29, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Clinical trial Presented 24-week interim biomarker data for neflamapimod in nonfluent variant PPA. In the upper-tertile drug exposure group (n=6), NfL fell a median 4.5 pg/mL over 24 weeks, while lower-tertile participants (n=12) rose a median 4.35 pg/mL. Full data expected in Q1 2027. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Earnings Reported Q3 2026 results: cash of $19.6 million as of September 30, 2026, funding operations through Q3 2027. R&D expenses were $3.7 million versus $6.0 million a year earlier, and net loss was $5.9 million versus $7.7 million. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 29, 2026 ·
Clinical trial Announced publication of two peer-reviewed articles on neflamapimod in DLB. The Phase 2b RewinD-LB placebo-controlled results did not confirm Phase 2a on the primary CDR-SB endpoint in the full population, but showed benefit in patients without AD co-pathology and a right basal forebrain MRI volume increase. Form 8-K · SEC filing · Press release
Oct 13, 2026 ·
Clinical trial Presented initial 12-week Phase 2a data for neflamapimod in nfvPPA showing mean plasma NfL change of about 3.1 pg/mL, with about 5.7 pg/mL decline in participants with baseline NfL at or above the median. GFAP was stable and no new safety signals emerged. Form 8-K · SEC filing · Press release
Oct 9, 2026 ·
CervoMed posted an investor presentation on its website under Events and Presentations for use at conferences and investor meetings. The company says the information is summary in nature and is not deemed filed under Section 18 of the Exchange Act. Form 8-K · SEC filing
Sep 28, 2026 ·
Regulatory CervoMed announced a new 50 mg neflamapimod tablet with a pharmacokinetic profile suited to twice-daily dosing, approximately 20% lower C max and approximately 20% higher C trough versus the prior 40 mg capsule. The FDA removed the prior plasma drug exposure limit, and the company plans a 100 mg twice-daily regimen. Form 8-K · SEC filing · Press release
Sep 10, 2026 ·
Clinical trial Announced that initial 12-week biomarker results from its Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia were accepted as a late-breaking oral presentation at the ISFTD Annual Meeting on October 11, 2026. The data will cover NfL and GFAP biomarkers from at least 22 participants. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2026 · Phase 2 · Active Trial · Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CRVO holds $19.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $6M/quarter from operations,
an estimated runway of 9.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 10 months +30
ATM program on file since May 2025 +15
Shelf registration (S-3, Oct 2024) +10
Going-concern doubt in the latest 10-Q +15Our cash resources are limited and management has concluded that substantial doubt exists about our ability to continue as a going concern.10-Q, Nov 2026
Share count 15,128,540 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CRVO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRVO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.